ReviewCells2020
GSK3β: A Master Player in Depressive Disorder Pathogenesis and Treatment Responsiveness.
Review in Cells, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 1 synthesis or guideline pooled it, 77 citations in OpenAlex.
- Systems-level transcriptomic analysis reveals synapse-related gene dysregulation in peripheral leukocytes of MDD patients.Scientific reports · 2026Pooled it
- Clinical Significance and Changes in Levels of Serum BDNF, mBDNF, AQP4, proBDNF, and GSK3β in Individuals Diagnosed With Bipolar Disorder: A Cross-Sectional Study.Health science reports · 2026Article
- Computational Repurposing of Asparagus racemosus and Withania somnifera for Postpartum Depression: Insights into MAO-A and Inflammatory Signaling Modulation.Cell biochemistry and biophysics · 2026Article
- USP11 drives stress-induced synaptic structural deficits and depression-like behaviors through GSK3β/mTOR signaling.Neurobiology of stress · 2026Article
- Article
- Medicinal Plants for Major Depressive Disorder.Brain sciences · 2026Review
- mPFC Synaptosome Proteomics Reveals Novel Pathways and Muscarinic Receptor Changes in a Learned Helplessness Mouse Model.bioRxiv : the preprint server for biology · 2026Article
- Sex-Dependent Effects of Circadian Rhythm Disruptions on Novel Object Recognition Memory, Locomotion, Pain Threshold, Rearing Behavior, and BDNF and GSK-3β Hippocampal Levels in Rats.Behavioural neurology · 2026Article
- Network pharmacology of cellular targets in major depressive disorder and differential mechanisms of fluoxetine, ketamine and esketamine.Computational and structural biotechnology journal · 2026Article
- Molecular Mechanisms of Emerging Antidepressant Strategies: From Ketamine to Neuromodulation.International journal of molecular sciences · 2025Review
- STAT3 Signaling Mediates Agomelatine Restoration of Prefrontal Cortex Synaptic Plasticity in Chronic Social Defeat Stress Mice.Molecular neurobiology · 2025Article
- Different Protocols of Circadian Rhythm Disruptions Differentially Affect Locomotor Activity, and Anxiety- and Compulsive-Like Behaviors in Male vs. Female Wistar Rats along with the Significant Involvement of GSK-3β in Females.Molecular neurobiology · 2025Article
- Downregulation of p120 catenin in the mouse hippocampus contributes to the development of depression-like phenotypes.Behavioral and brain functions : BBF · 2025Article
- Dysregulated miR-1246 and miR-1253 link inflammatory protein markers in plasma to major depressive disorder in female adolescents.Brain, behavior, & immunity - health · 2025Article
- The Differential Involvement of α1-Adrenoceptor Subtypes in the Molecular Effects of Antidepressant Drugs.International journal of molecular sciences · 2025Article
- Genetically proxied glucagon-like peptide-1 receptor perturbation and risk of mood disorders: a Mendelian randomization study.BMC psychiatry · 2025Article
- Soyasaponin Bb Attenuates Morphine Withdrawal-Induced Anxiety-Like Behaviors in Male Mice by Rescuing GSK-3β/Nrf2 Signaling.Psychiatry investigation · 2025Article
- Chronic, combinatorial targeting of NMDARs and 5-HTNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2025Article
- Review
- Xenon gas as a potential treatment for opioid use disorder, alcohol use disorder, and related disorders.Medical gas research · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glycogen synthase kinase 3β (GSK3β), originally described as a negative regulator of glycogen synthesis, is a molecular hub linking numerous signaling pathways in a cell. Specific GSK3β inhibitors have anti-depressant effects and reduce depressive-like behavior in animal models of depression. Therefore, GSK3β is suggested to be engaged in the pathogenesis of major depressive disorder, and to be a target and/or modifier of anti-depressants' action. In this review, we discuss abnormalities in the activity of GSK3β and its upstream regulators in different brain regions during depressive episodes. Additionally, putative role(s) of GSK3β in the pathogenesis of depression and the influence of anti-depressants on GSK3β activity are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.